

## LIDDS is re-organising in Medical and Business Development

**UPPSALA, SWEDEN – LIDDS AB (publ) announces today that the following changes to its organisation have been implemented.**

Previous part-time Chief Medical Officer, Dr. Johan Harmenberg, has been replaced by Dr. Roger Belusa on a consultancy basis. Also, Annette Møldrup who was on a probation employment contract as CBDO has left the company, and the Business Development function is instead managed directly by CEO Anders Månsson and extended through the company's collaboration with Alira Health as previously announced.

"Dr. Johan Harmenberg informed me already in the autumn last year of his desire to focus his efforts on his ambitions as a politician in Region Stockholm. LIDDS has found an excellent replacement for him in the Medical Advice function in Dr. Roger Belusa, and the transition has been smooth" says Anders Månsson, CEO of LIDDS. "Business Development is obviously a critical factor for LIDDS now, and given this and considering my background, I view it as natural that I assume direct operational leadership of this function. In this capacity I have also already extended the company's capabilities and reach through the collaboration agreement with Alira Health, and given this as well as for reasons of cost effectiveness, I have not prolonged the contract with Annette Møldrup. I would however like to extend sincere thanks to both Johan and Annette for their services to the company and, of course, also extend my great appreciation for Roger Belusa's desire to join LIDDS" Anders Månsson continues.

**For additional information, please contact**

---

Anders Månsson, CEO  
Phone: +46 (0)70 860 47 38  
E-mail: [anders.mansson@liddspharma.com](mailto:anders.mansson@liddspharma.com)

Jenni Björnulfson, CFO  
Phone: +46 (0)70 855 38 05  
E-mail: [jenni.bjornulfson@liddspharma.com](mailto:jenni.bjornulfson@liddspharma.com)

LIDDS' Certified Adviser is Redeye AB

**LIDDS in brief:**

---

LIDDS is a Swedish drug delivery company based on the proprietary technology NanoZolid®. With NanoZolid®, LIDDS can formulate drugs for local/intratatumoral administration, with a maintained and controlled release for up to six months. The technology is versatile, can be used across different drug classes and can solve problems within many indication areas, mainly within oncology. LIDDS offers the NanoZolid® technology to partners and has developed its own pipeline focused on oncology, where the technology enables delivery of a local and high drug dose, administered over time with very limited side effects. LIDDS has a broad pipeline with several projects in clinical development, both in early and late-stage clinical phase, and projects about to enter clinical development. The company is listed on Nasdaq First North Growth Market.

**Attachments**

---

**LIDDS is re-organising in Medical and Business Development**